Tarsus Pharmaceuticals recently acquired Alkeus Pharmaceuticals, gaining worldwide rights to gildeuretinol, a promising Phase 3 drug for Stargardt's disease, which currently lacks FDA-approved treatments. Analyst Jefferies raised Tarsus' price target to $105, indicating a 17.1% potential upside from the current stock price. This acquisition strengthens Tarsus' position in eye care and expands its drug pipeline with a treatment showing positive clinical results in reducing retinal lesion growth. The move is seen as a strategic step to enhance growth and innovation in retinal disease therapies.
GameStop reported Q2 2026 revenue of $790.20 million, beating analyst estimates but showing a 19% year-over-year decline due to a strong prior year and strategic store closures. The company's Collectibles segment grew 57% to $356.30 million, offsetti...
Raymond James analyst Michael Freeman raised Dyne Therapeutics' price target to $37, suggesting an 80.75% upside from its current price around $20.60. The clinical-stage biotech is advancing treatments for muscle diseases like Myotonic Dystrophy Type...
17 Education & Technology Group Inc. (17EdTech) will release its Q3 earnings on September 8, 2026, with analysts forecasting a loss of $8.60 per share and revenue of $73.47 million. Despite ongoing unprofitability, the company maintains strong financ...
Roivant Sciences saw its price target raised to $52 by Jefferies, reflecting a 24.7% potential gain, following positive Phase 2 trial results for mosliciguat, a drug treating pulmonary hypertension linked to interstitial lung disease. The trial showe...
EVI Industries reported Q4 revenue of $121.87 million, surpassing analyst expectations of $117.1 million, and achieved a record fiscal year revenue of $446.6 million, marking a 15% increase year-over-year. The company met earnings per share forecasts...
